Abstract
Background: Neutrophil gelatinase-associated lipocalin (NGAL) has been suggested as the most promising biomarker of acute kidney injury. However, there are no reliable data on analytical sensitivity and reference limits of urinary NGAL (uNGAL) assay in pediatric age. The aim of the present study is to evaluate the analytical sensitivity and the reference range of uNGAL measured in urine specimens of pediatric age with the fully automated platform ARCHITECT® i1000.
Methods: A total of 333 urine samples were collected from 25 healthy newborns (16 males and 9 females; age 1–4 days) and 308 children (150 males and 147 females; mean age 80.7 months, range 0.63–248 months) and assayed for uNGAL by two different Italian centers (Department of Laboratory Medicine of the Fondazione Toscana G. Monasterio of Pisa and Massa and the Clinical Pathology Laboratory Unit of Istituto Giannina Gaslini of Genova).
Results: The calculated limits of blank (LOB) and detection (LOD) values were 0.5 ng/mL and 0.95 ng/mL, respectively. The distribution of uNGAL values approximated a log-normal distribution (median 5.2 ng/mL, interquartile range 2.5–12.8 ng/mL, 99th percentile 117.6 ng/mL). uNGAL values of the 25 neonates were significantly higher than those of 308 children (neonates: mean 44.2 ng/mL, median 30.3 ng/mL, range 5.2–137.4 ng/mL; children: mean 10.2 ng/mL, median 4.6 ng/mL, range 0.2–146.7 ng/mL; p<0.0001).
Conclusions: uNGAL assay shows a good analytical sensitivity and imprecision, which allows the measurement of uNGAL values around the cut-off value (i.e., 117.6 ng/mL) with an imprecision <5 CV%. The distribution of uNGAL values in pediatric age approximates a log-normal distribution, with values which are higher in neonates compared to children.
Abbott Diagnostic Division Italia (Rome, Italy) kindly supplied all reagents and calibrators used in the study.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research sponsoring played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;53:961–73.10.1053/j.ajkd.2008.11.034Search in Google Scholar PubMed PubMed Central
2. Devarajan P. Neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology 2010;15:419–28.10.1111/j.1440-1797.2010.01317.xSearch in Google Scholar PubMed
3. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:1012–24.10.1053/j.ajkd.2009.07.020Search in Google Scholar PubMed
4. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of Neutrophil Gelatinase-Associated Lipocalin-positive subclinical acute kidney injury – a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011;57:1752–61.10.1016/j.jacc.2010.11.051Search in Google Scholar PubMed PubMed Central
5. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury (AKI): the laboratory point of view. Clin Chem Lab Med 2012;50:1505–17.10.1515/cclm-2011-0814Search in Google Scholar PubMed
6. Grenier FC, Ali S, Syed H, Workman R, Martens F, Liao M, et al. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin Biochem 2010;43:615–20.10.1016/j.clinbiochem.2009.12.008Search in Google Scholar PubMed
7. Cavalier E, Bekaert AC, Carlisi A, Legrand D, Krzesinski JM, Delanaye P. Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory’s point of view. Clin Chem Lab Med 2011;49:339–41.10.1515/CCLM.2011.044Search in Google Scholar PubMed
8. National Institute for Health and Clinical Excellence. Urinary tract infection in children. London: NICE, 2007. (http://guidance.nice.org.uk/CG054).Search in Google Scholar
9. CLSI EP17-A protocol. Protocols for determination of limits of detection and limits of quantitation; approved guidelines. Vol. 24. Wayne, PA: CLSI, 2004.Search in Google Scholar
10. CLSI EP5-A2 protocol. Evaluation of precision performance of quantitative measurement methods; Approved guideline, 2nd ed. Vol. 24. Wayne, PA: CLSI, 2004.Search in Google Scholar
11. Huynh TK, Bateman DA, Parravicini E, Lorenz JM, Nemerofsky SL, Sise ME, et al. Reference values of urinary neutrophil gelatinase-associated lipocalin in very low birth weight infants. Pediatr Res 2009; 66:528–32.10.1203/PDR.0b013e3181baa3ddSearch in Google Scholar PubMed PubMed Central
12. Pedersen KR, Ravn HB, Hjortdal VE, Nørregaard R, Povlsen JV. Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scand J Clin Lab Invest 2010;70:374–82.10.3109/00365513.2010.486868Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
